Chair: Ulrika Johansson (UK)
Co-chair: Jan Willem Gratama (the Netherlands)
Committee Members: Formed from lead participants in individual projects
Aim: To develop working groups that identify, validate and publish consensus approaches for clinical diagnostic cytometry. The European Working Group for Clinical Cell Analysis was founded in 1996 to develop consensus in clinical cytometry and ESCCA continues this effort in the harmonisation committee. Andy has been involved in more than 15 consensus projects over the past two decades, in collaboration with several international groups including ICCS, Euroflow, EMN, and ERIC. The ESCCA harmonisation group identifies relevant topics by survey of the members to determine the most pressing requirements for harmonisation and validation. Based on the experience of many different consensus project, the proposed approach for subsequent harmonisation projects is as follows:
Develop laboratory and clinical working groups for specific diagnostic topics Survey members to identify consensus on required (for all resource settings) vs. recommended markers for diagnosis / monitoring Identify positive and negative controls, preferably in normal peripheral blood, and calculate an appropriate relative signal on the control populations that can be used to specify appropriate reagents Define a consensus approach and test this retrospectively if possible. Confirm the consensus after consultation with members and publish.
Test the consensus approach prospectively and identify diagnostic challenges The ESCCA harmonisation group has successfully completed two consensus projects so far:
Immunodeficiency Working Group
Chair: Ulrich Sack (Germany)
Committee Members: Gulderen Demirel (Turkey), Marianna Tzanoudaki (Greece), Frank Preijers (the Netherlands)
Aim: ESCCA Working Group on Immunodeficiencies intends to strengthen research and clinical application of flow cytometry in Clinical Immunology. The target is to establish, to improve, and to harmonize approaches for immunodeficiency detection, monitoring, and treatment.
To do so, WG-ID will: